

Special Issue

Nutrition in Cancer Care: From Generalized to Personalized Adjunctive Therapy

Message from the Guest Editor

Standard cancer treatments frequently rely on generalized dosing protocols, such as body surface area (BSA), which often overlook individual metabolic variability. This Special Issue explores the critical shift from these "one-size-fits-all" approaches to personalized adjunctive therapies. We aim to investigate how anthropometric and nutritional parameters influence treatment efficacy and toxicity. Key topics include the impact of host factors on immunotherapy outcomes and survival in recurrent or metastatic cases, and the potential of adjunctive agents, such as statins, to modulate chronic inflammation. Furthermore, we invite research on therapeutic drug monitoring (TDM) to optimize pharmacokinetics (e.g., for 5-FU) based on nutritional status. This collection seeks to establish evidence for personalized strategies that enhance clinical outcomes by accounting for individual metabolic differences. The purpose of this Special Issue is to present the new insights into how anthropometric and nutritional parameters influence cancer treatment outcomes, facilitating the transition from standardized dosing to personalized therapeutic strategies.

Guest Editor

Dr. Mitsuyoshi Urashima

Division of Molecular Epidemiology, Jikei University School of Medicine,
Nishi-shimbashi 3-25-8, Minato-ku, Tokyo 105-8461, Japan

Deadline for manuscript submissions

6 January 2027



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/267441

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)